Gestational weight gain · pregnant women with pre‐existing type 1 diabetes
1 finding from 1 review
Postnatal depression · pregnant women with pre‐existing type 1 diabetes
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Induction of labour · pregnant women with pre‐existing type 1 diabetes
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Later development of cardiovascular disease · pregnant women with pre‐existing type 1 diabetes
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Large‐for‐gestational age · pregnant women with pre‐existing type 1 diabetes
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Perinatal mortality · pregnant women with pre‐existing type 1 diabetes
1 finding from 1 review
Pain‐free response at 2 h for mild baseline pain · adults with migraine headache ‐ moderate or severe and mild baseline pain
1 finding from 1 review
no estimate extracted
Studies not reported
High
Sustained pain‐free during the 24 h post dose for mild baseline pain · adults with migraine headache ‐ moderate or severe and mild baseline pain
1 finding from 1 review
no estimate extracted
Studies not reported
High
At least 1 AE during treatment for mild baseline pain · adults with migraine headache ‐ moderate or severe and mild baseline pain
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Serious AE (all levels of baseline pain) · adults with migraine headache ‐ moderate or severe and mild baseline pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Any adverse event (combined: diarrhoea, urinary tract infection, falls, dizziness, agitations) · Apathy in people with mild‐to‐moderate Alzheimer's disease
Omega‐3 PUFA supplements showed no clear difference in any adverse event (combined: diarrhoea, urinary tract infection,… compared with placebo (moderate certainty).
1 finding from 1 review
ADL outcome · Apathy in people with mild‐to‐moderate Alzheimer's disease
1 finding from 1 review
Overall dementia severity (cognition and function combined) · Apathy in people with mild‐to‐moderate Alzheimer's disease
1 finding from 1 review
Memory ‐ not measured · Apathy in people with mild‐to‐moderate Alzheimer's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events "Defined as events that result in death, hospitalization, prolongation of hospitalization, or are life threatening (based on the judgment of the study physician)" (Quinn 2010) · Apathy in people with mild‐to‐moderate Alzheimer's disease
Omega‐3 PUFA supplements showed no clear difference in serious adverse events "Defined as events that result in death,… compared with placebo (high certainty).
1 finding from 1 review
QoL · Apathy in people with mild‐to‐moderate Alzheimer's disease
2 findings from 1 review
Depressive symptoms · Apathy in people with mild‐to‐moderate Alzheimer's disease
1 finding from 1 review
Mental health outcomes · Apathy in people with mild‐to‐moderate Alzheimer's disease
1 finding from 1 review
Cognitive function · Apathy in people with mild‐to‐moderate Alzheimer's disease
2 findings from 1 review
IADL · Apathy in people with mild‐to‐moderate Alzheimer's disease
1 finding from 1 review